Skip to main content
. 2021 Mar 2;13(1):1870402. doi: 10.1080/19490976.2020.1870402

Table 1.

Summary of included studies: author, year, location, design, aim, participants, antibiotic, duration, molecular techniques used, and outcomes

Author, year, location Design
and reference group
Aim Study participants (n), age Antibiotic exposure
(route; duration)
Exposure to outcome interval (sampling frequency) Molecular technique Key findings:
Richness
Key findings:
Diversity
Key findings:
Taxonomical change
1.Bai et al.32
China
Cross-sectional with
(control group)
Added impact of antibiotics on microbiota changes in ALL 33 healthy children;
10 received antibiotics
1–12 years
Cephalosporin
Penicillin
(oral + IV:
10 days)
1–4 weeks
(x1)
Next generation sequencing (NGS) n/a Reduction in α-diversity
Shannon index, ~2.75 (antibiotics) vs ~3.25 (control), p < .05 #
Simpson index ~0.15 (antibiotics) vs ~0.09 (control) p < .05 # a
Decreased Firmicutes/Bacteroidetes ratio by approximately one third (p < .05)
No difference in abundances of Actinobacteria and Proteobacteria
2. Bokulich et al,33
USA
Cohort
(baseline assessment)
Microbiome development in first 2 years of life 43 infants, 25 received antibiotics
0–2 years
Cephalosporin
Beta-lactams
Macrolides
Quinolones
Nitrofurantoin
(route/duration not
specified)
3–139 days
(x25)
PCR, 16s RNA gene
amplification
n/a No change in α-diversity after antibiotic exposure for median 52 days (13–139)
Reduced β–diversity: UniFrac distance, Permutational MANOVA, R2 < 0.01, p < .001
No effect on Bifidobacterium abundance
3.Brunser et al.34
Chile
RCT
(baseline assessment)
Impact on microbiome of prebiotic supplement following antibiotic 130 infants, before and after antibiotics
1–2 years
Amoxicillin
(oral; 7 days)
1–3 weeks
(x3)
FISH* and flow cytometry n/a n/a Decrease in amoxicillin-associated fecal bacteria by 30% (p < .001)
Increase in amoxicillin associated E. Coli Log count 4.77 ± 0.96 (baseline) vs 5.10 ± 1.39 after treatment (p = .015)
No change in total counts of Bifidobacterium and Bacteroides
4.Doan et al.35
Niger
RCT
(control group)
Effects of azithromycin on gut microbiome diversity 80 children, 40 received antibiotics
1–5 years
Azithromycin
(oral; single dose)
5 days
(x1)
16S rRNA sequencing n/a Reduction in α-diversity:
Inverse Simpson’s α-diversity decreased (5.03 95% CI 4.08–6.14) vs placebo (6.91; 5.82 − 8.21) p = .03
Shannon’s α-diversity decreased (10.60; 95% CI 8.82–12.36) vs placebo (15.42; 13.24–17.80) p = .004
No change in β-diversity
Decrease in Simpson’s community level γ diversity with azithromycin (10.10 95% CI 7.80–11.40) vs placebo (17.72;13.80–20.21) (p < .001)
n/a
5.Fouhy et al.36
Ireland
Cohort study (control group) Effect of antibiotics on gut microbiome 18 children, 9 received antibiotics
Newborn
Ampicillin and gentamicin
(IV:2–9 days)
4 and 8 weeks
(x2)
High throughput sequencing of 16S rRNA n/a No change in α-diversity (Shannon Index) at 4 weeks (3.6) vs control (3.6) (p = .575) Decreased Bifidobacterium (5% vs 25%; p = .013) and Lactobacillus (1% vs 4%; p < .009) in treated group at 4 weeks vs control; no difference at 8 weeks
Increased Proteobacteria (44% vs 23%; p < .005)
and Enterobacteriaceae (50% vs 32%; p = .006) at 8 weeks vs control.
Increased Clostridium in treated infants than controls at week 8 (7% vs 2%, p < .035)
6.Korpela et al.37
Finland
Retro-spective controlled cohort study Antibiotic induced changes in microbiota composition 142 children, 99 received antibiotics
2–7 years
Macrolides Penicillins
(route/duration not specified)
Variable
(<6 months to 2 years)
(x1-2)
DNA extraction, 16s rRNA gene sequencing Macrolides:
Reduced richness up to 2 years (p < .05)#
Penicillins: Reduced richness over 6 months# (p < .001)resolved by 12 months
n/a Macrolides: Exposure over 6 months
Reduced Bifidobacterium (0.23-fold change p < .004) and Lactobacillus (0.12-fold change p < .004)
Increased Bacteroides (2.04-fold change p < .004) and Proteobacteria (1.96-fold change (p < .02).
Penicillins:
Decreased Lactobacillus (0.09 fold; p < .004) with exposure in previous 12 months
7.Mangin et al.38
Chile
Cohort
(baseline assessment)
Impact of amoxicillin on fecal bifidobacteria 31 infants, all received antibiotics
12–24 months
Amoxicillin
(oral: 7 days)
0 days
(x2)
Total DNA extraction, PCR n/a n/a No change in total Bifidobacteria
Disappearance of Bifidobacterium adolescentis species (0% vs 36.4% (p < .001)
8. Oldenburg et al.39
Burkina Faso
RCT
(baseline assessment)
Investigate effect of 3 antibiotics on microbial diversity 124 children, 93 received antibiotics
6–59 months
Amoxicillin
Azithromycin
Cotrimoxazole
(oral: 5 days)
5 days
(x2)
DNA extraction, deep gene sequencing n/a Reduced α- diversity with Azithromycin:
Inverse Simpsons’ index decreased (6.6 95% CI 5.5–7.8) vs baseline (8.8 95% CI 7.5–10.1) (p < .001)
Shannon index decreased (11.0 95% CI 9.3–12.7) vs baseline (14.6 95% CI 13.0–16.2) (p < .001)
No reduction with Amoxicillin or Cotrimoxazole
n/a
9.Parker et al.40
India
RCT
(baseline assessment)
Assess microbiota changes following azithromycin 114 infants,
56 received antibiotics
6–11 months
Azithromycin
(oral: 3 days)
12 days
(x2)
16s rRNA gene sequencing, DNA extraction
PCR
Lower OTU with azithromycin: (68.1 ± 15.4) vs placebo (73.6 ± 13.7) (linear regression p = .027) c. 7% less No significant change in α-diversity (Shannon index) azithromycin (2.6 95%CI 2.47–2.73) vs placebo (2.8 95%CI 2.8(2.67–2.93) (p = .087) Decreased relative abundance of Proteobacteria (mainly Escherichia) mean % ± SD: 15.9 ± 13.2 vs 10.2 ± 15.4 FDR (p < .001) and Verrucomicrobia (genus Akkermansia muciniphilia) 0.5 ± 3.1 vs 0.0 ± 0.0 FDR (p < .012)
No change in Actinobacteria, Bacteroides and Firmicutes, Bifidobacterium
10.Penders et al.41
The Netherlands
Cross Sectional
(control group)
Examine contribution of external influences to gut microbiota composition 1032 infants,
28 received antibiotics
1 month
Mainly Amoxicillin
(oral: duration not specified)
<1 month
(x1)
DNA isolation, PCR n/a n/a Decrease with antibiotics in Bifidobacteria. Antibiotics (10.29 CFU/g log10) vs Control (10.7 CFU/g log10 (p < .01)
Decrease in Bacteroides fragilis. Antibiotics (6.39 CFU/g log10) vs Control (9.31 CFU/g log10) (p < .01)
No change in Lactobacilli, Escherichia coli, Clostridium difficile
11. Wei et al.29
Denmark
RCT
(control group)
Examine short- and long-term impacts of azithromycin treatment on gut microbiota in children 72 children, 33 episodes of asthma-like symptoms received antibiotics
12–36 months
Azithromycin
(oral: 3 days)
14 days and up to 4 years
(x3)
DNA extraction and sequencing Decrease in richness at 14 days: Observed richness: 23% reduction (177.8 ± 56.0 vs. 230.6 ± 61.2, p < .001); no difference by mean 233 days Reduced α-diversity:
at 14 days: Shannon index: 13% reduction; 2.96 ± 0.80 (mean ± SD) vs control 3.41 ± 0.58, p = .009)
Reduced β–diversity:
UniFrac distance, treatment accounted for variance (R2 = 3.8%, p = .027 (weighted) and F2 = 4.2% p < .001 (un-weighted)
Reduction, 50-fold, in genus Bifidobacterium at 14 days (p adjusted <0.011 (FDR p < .05)
Long term (13–39 months) no differences seen between azithromycin and placebo groups
12.Yassour et al.42
Finland
Cohort
(control group)
Study development of infant gut microbiome and effect of antibiotics 39 children,
20 received antibiotics
2–36 months
Amoxicillin
Cefalexin
Clarithromycin Amoxicillin and clavulanic acid Trimethoprim and sulfadiazine
Azithromycin Cefaclor
Penicillin G Netilmicin
(oral: duration not specified)
<1 month
(x28)
16S rRNA gene and
whole genome shotgun sequencing
n/a Reduced microbiome strain (subspecies) diversity (diversity index 0.0003 vs 0.55 (control) (p < .001) Decreased abundance of species from clostridium clusters IV and XIVa (T regulatory immune cells) at aged 3 (median abundance ~9% vs ~15% control)b (p = .037)
Less stable gut microbiome following antibiotic treatment (Jaccard Index P = <0.001)

Key: # – Approximate mean values taken from a Box and Whisker plot; ꝉ – statistical significance testing, confidence intervals, or standard deviations not given; a – higher the Simpson index, the lower the diversity; b -raw data not given, approximate values taken from graph

Abbreviations: n/a- data not available. ALL: acute lymphoblastic leukemia. CFU/g = Colony forming units per gram of sample. FISH: Fluorescent in-situ hybridization. FDR – False Discovery Rate correction. OTU count: operational taxonomical unit.